Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter

FEBS Letters

Volumn 586, Issue 3, 2012, Pages 248-253

  Grempler, Rolf ^a   Augustin, Robert ^a   Froehner, Stefanie ^c   Hildebrandt, Tobias ^a   Simon, Eric ^a   Mark, Michael ^a   Eickelmann, Peter ^b  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Empagliflozin; Kidney; Mannose; SGLT; Sodium glucose cotransporters

Indexed keywords

ALPHA METHYLGLUCOSIDE; CANAGLIFLOZIN; CARBON 14; DAPAGLIFLOZIN; EMPAGLIFLOZIN; FRUCTOSE; GALACTOSE; GLUCOSE; MANNOSE; MESSENGER RNA; PHLORIZIN; REMOGLIFLOZIN ETABONATE; SODIUM; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 5; UNCLASSIFIED DRUG;

ARTICLE; CARBOHYDRATE TRANSPORT; CONTROLLED STUDY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INHIBITION KINETICS; KIDNEY PARENCHYMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE SPECIFICITY;

ABSORPTION; BIOLOGICAL TRANSPORT; CLONING, MOLECULAR; GENE EXPRESSION REGULATION; GLUCOSE; HEK293 CELLS; HUMANS; KIDNEY; ORGAN SPECIFICITY; PHLORHIZIN; PROTEIN ISOFORMS; PROTEIN STABILITY; RNA, MESSENGER; SODIUM-GLUCOSE TRANSPORTER 1;

EID: 84856212857     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2011.12.027     Document Type: Article

References (27)

1. E.M. Wright, D.D. Loo, and B.A. Hirayama Biology of human sodium glucose transporters Physiol. Rev. 91 2 2011 733 794
2. E.M. Wright, B.A. Hirayama, and D.F. Loo Active sugar transport in health and disease J. Intern. Med. 261 1 2007 32 43 (Pubitemid 46046470)
3. C.S. Hummel, C. Lu, D.D. Loo, B.A. Hirayama, A.A. Voss, and E.M. Wright Glucose transport by human renal Na+/d-glucose cotransporters SGLT1 and SGLT2 Am. J. Physiol. Cell Physiol. 300 1 2011 C14 C21
4. H. Bays From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus Curr. Med. Res. Opin. 25 3 2009 671 681
5. A. Diez-Sampedro, B.A. Hirayama, C. Osswald, V. Gorboulev, K. Baumgarten, C. Volk, E.M. Wright, and H. Koepsell A glucose sensor hiding in a family of transporters Proc. Natl. Acad. Sci. USA 100 20 2003 11753 11758 (Pubitemid 37206007)
6. D. O'Malley, F. Reimann, A.K. Simpson, and F.M. Gribble Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing Diabetes 55 12 2006 3381 3386 (Pubitemid 44923596)
7. S. Tazawa, T. Yamato, H. Fujikura, M. Hiratochi, F. Itoh, M. Tomae, Y. Takemura, H. Maruyama, T. Sugiyama, A. Wakamatsu, T. Isogai, and M. Isaji SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-d-glucitol, and fructose Life Sci. 76 9 2005 1039 1050 (Pubitemid 39643403)
8. M.J. Coady, B. Wallendorff, D.G. Gagnon, and J.Y. Lapointe Identification of a novel Na+/myo-inositol cotransporter J. Biol. Chem. 277 38 2002 35219 35224
9. R. Aouameur, C.S. Da, P. Bissonnette, M.J. Coady, and J.Y. Lapointe SMIT2 mediates all myo-inositol uptake in apical membranes of rat small intestine Am. J. Physiol. Gastrointest. Liver Physiol. 293 6 2007 G1300 G1307
10. R. Santer, and J. Calado Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target Clin. J. Am. Soc. Nephrol. 5 1 2010 133 141
11. E.C. Chao A paradigm shift in diabetes therapy - dapagliflozin and other SGLT2 inhibitors Discov. Med. 11 58 2011 255 263
12. Suzuki, M., Honda, K., Fukazawa, M., Ozawa, K., Hagita, H., Kawai, T. and Ikeda, S. (2011) Tofogliflozin, a novel, potent, and highly specific selective SGLT2 inhibitor, improves glycemic control in diabetic mice and rats. American Diabetes Association Annual Meeting, 1136-P.
13. E. Ferrannini Learning from glycosuria Diabetes 60 3 2011 695 696
14. S. Leicht, S. Grohmann, K. Page, R. Streicher, M. Mark, and P. Eickelmann hSGLT5 (SLC5A10) is a sodium dependent sugar transporter exclusively expressed in the kidney Diabetes 55 2006 1512-P
15. J. Chen, S. Wiliams, S. Ho, H. Loraine, D. Hagan, J. Whaley, and J. Feder Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members Diabetes Ther 1 2 2010 57 92
16. M. Nishimura, and S. Naito Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies Drug Metab. Pharmacokinet. 20 6 2005 452 477
17. R. Grempler, L. Thomas, M. Eckhardt, F. Himmelsbach, A. Sauer, D.E. Sharp, R.A. Bakker, M. Mark, T. Klein, and P. Eickelmann Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors Diabetes Obes. Metab. 2011 [Epub ahead of print]
18. T. Taguchi, E. Yamashita, T. Mizutani, H. Nakajima, M. Yabuuchi, N. Asano, and I. Miwa Hepatic glycogen breakdown is implicated in the maintenance of plasma mannose concentration Am. J. Physiol. Endocrinol. Metab. 288 3 2005 E534 E540
19. E. Pitkanen Mannose, mannitol, fructose and 1,5-anhydroglucitol concentrations measured by gas chromatography/mass spectrometry in blood plasma of diabetic patients Clin. Chim. Acta 251 1 1996 91 103 (Pubitemid 26227629)
20. H. Sone, H. Shimano, H. Ebinuma, A. Takahashi, Y. Yano, K.T. Iida, H. Suzuki, H. Toyoshima, Y. Kawakami, Y. Okuda, Y. Noguchi, K. Ushizawa, K. Saito, and N. Yamada Physiological changes in circulating mannose levels in normal, glucose-intolerant, and diabetic subjects Metabolism 52 8 2003 1019 1027 (Pubitemid 37098371)
21. T. Taguchi, I. Miwa, T. Mizutani, H. Nakajima, Y. Fukumura, I. Kobayashi, M. Yabuuchi, and I. Miwa Determination of d-mannose in plasma by HPLC Clin. Chem. 49 1 2003 181 183 (Pubitemid 36078572)
22. M. Soleimani Dietary fructose, salt absorption and hypertension in metabolic syndrome: towards a new paradigm Acta Physiol. (Oxf) 201 1 2011 55 62
23. R.J. Johnson, L.G. Sanchez-Lozada, and T. Nakagawa The effect of fructose on renal biology and disease J. Am. Soc. Nephrol. 21 12 2010 2036 2039
24. C.J. Bailey, J.L. Gross, A. Pieters, A. Bastien, and J.F. List Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial Lancet 375 9733 2010 2223 2233
25. R.L. Dobbins, R. O'Connor-Semmes, A. Kapur, C. Kapitza, G. Golor, I. Mikoshiba, W. Tao, and E.K. Hussey Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2) reduces serum glucose in type 2 diabetes mellitus patients Diabetes Obes. Metab. 2011 [Epub ahead of print]
26. J. Rosenstock, A. Jelaska, L. Seman, S. Pinnetti, S. Hantel, and H.J. Woerle Efficacy and safety of BI 10773, a new sodium glucose cotransporter (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin Diabetes 60 Suppl. 1 2011 A271 [989-P]
27. F. Birzele, J. Schaub, W. Rust, C. Clemens, P. Baum, H. Kaufmann, A. Weith, T.W. Schulz, and T. Hildebrandt Into the unknown: expression profiling without genome sequence information in CHO by next generation sequencing Nucleic Acids Res. 38 12 2010 3999 4010